Anticancer research peptide that selectively targets membrane-associated HDM-2 on tumor cells, inducing membranolysis without affecting normal cells.
Last Updated: May 2026
PNC-27 is a synthetic anticancer research peptide designed to selectively target membrane-associated HDM-2 (mouse double minute 2 homolog) on tumor cell surfaces, inducing membranolysis (cell membrane destruction) without affecting normal cells. It is one of the more mechanism-distinctive cancer research peptides, with selective tumor cell killing through a specific membrane interaction rather than DNA damage or cell-cycle arrest. PNC-27 is not approved for any medical indication and is sold as a research-use-only compound by third-party laboratories. Important framing: PNC-27 is a preclinical-stage research compound; despite community marketing in some contexts, no human clinical trials have demonstrated cancer efficacy.
PNC-27 is a synthetic 32-amino-acid peptide combining the p53 binding region for HDM-2 with a membrane-residency signal sequence, designed to bind membrane-localized HDM-2 (which is selectively expressed on tumor cell surfaces but minimally on normal cells) and induce direct membranolysis. The tumor-selective targeting depends on the differential expression of membrane-associated HDM-2 between malignant and normal cells. Evidence level: Preclinical (cell culture, rodent xenograft models); no published human clinical trials.
Preclinical studies have demonstrated selective tumor cell killing in cell culture across multiple cancer types and tumor regression in rodent xenograft models. The mechanism is mechanistically interesting because membrane-localized HDM-2 represents a tumor-selective surface target. Despite preclinical promise, no published human clinical trials have established PNC-27 efficacy or safety at any clinical stage. Evidence level: Preclinical (cell culture, rodent xenografts); no human clinical trials.
PNC-27 occupies a niche in research peptides with anticancer mechanisms, distinguished by its preclinical-only evidence base and the absence of formal clinical development. Most truly evidence-based cancer treatments are administered through approved oncology pathways.
| Compound | Anticancer mechanism | Evidence stage | Available context |
|---|---|---|---|
| PNC-27 | Membrane HDM-2 targeting, selective membranolysis | Preclinical only | Research use only |
| Adipotide | Vascular-targeted apoptosis | Phase 1 (halted) | Research use only |
| Approved cancer therapeutics | Various (chemo, targeted, immune) | Approved | Oncology medical care |
Human safety data for PNC-27 is absent — no published human clinical trials. Preclinical rodent studies have not surfaced major toxicity signals at researched doses, but the selective tumor-targeting depends on membrane HDM-2 expression patterns that may vary individually. Long-term safety in humans is completely unknown. Evidence level: Preclinical safety only; no human safety data.
PNC-27 is not approved for any cancer or other medical indication anywhere in the world as of May 2026. No active human clinical trial program has been registered for PNC-27. The compound is sold strictly as a research-use-only material by third-party laboratories. Patients with active cancer should pursue treatment through licensed oncology care; PNC-27 is not an evidence-based cancer therapy at the human level. Regulatory context in are peptides legal regulatory status by country.
Because PNC-27's structural complexity (32 amino acids with specific binding-region and membrane-residency-signal architecture) requires substantial synthesis quality control, and incorrectly synthesized material may have altered mechanism — but also because the absence of human clinical evidence means buyers may be paying for something that cannot be expected to produce the marketed effect even when correctly synthesized. Independent HPLC purity testing and mass spectrometry are the standard quality signals. Guidance in how-to-test-peptides hub.
Peptigrity purchases PNC-27 vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. Methodology in how we calculate trust scores.
No. PNC-27 is a preclinical research compound with no published human clinical trials demonstrating cancer efficacy or safety. Despite community marketing in some contexts suggesting cancer benefits, no human evidence exists. Anyone with active cancer should pursue evidence-based treatment through licensed oncology care, not unproven research peptides.
PNC-27 is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. Country breakdown in peptide legal status guide.
No active FDA clinical development program for PNC-27 exists as of May 2026. Approval is unlikely without a registered Phase 1 trial program, which has not been initiated.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Note that purity verification does not address the underlying issue: PNC-27 has no published human efficacy data regardless of synthesis quality. COA interpretation in red flags in peptide certificates of analysis.
No. PNC-27 has no published human clinical data and Peptigrity is an independent review platform, not a medical authority. Anyone with active cancer or cancer concerns should pursue evidence-based oncology care.
PNC-27 is a mechanistically interesting preclinical research compound with selective tumor-cell-killing activity in cell culture and rodent xenograft models, but no published human clinical trials. It should not be considered a cancer therapy at the human level. Evidence-based cancer treatment exists in oncology medicine and should be the first-line consideration for anyone with active cancer.
This section is for educational and informational purposes only and does not constitute medical advice. PNC-27 is not approved by the FDA or any other regulator for human use and has no published human clinical trial data. Patients with active cancer should pursue evidence-based treatment through licensed oncology care, not unproven research peptides. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.